Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Citius Pharmaceuticals Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.76 (market cap $5.07B), while Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 253.4× Citius Pharmaceuticals Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | CTXR | |
|---|---|---|
Market Cap | $5.07B | $20.01M |
Sector | Health | Health |
52-Week High | $29.41 | $1.82 |
52-Week Low | $20.06 | $0.48 |
Enterprise Value | $4.19B | $16.23M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
